Figure 2From: A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia Kaplan-Meier time to discontinuation due to adverse events. There was no statistically significant difference between the LY2140023 and SOC groups in time to discontinuation due to lack of tolerability through 24 weeks (log-rank test; P = .184).Back to article page